FDA recommends UCB reformulate Neupro; Exponential Pharma and Benu form new company;

> The FDA has recommended that UCB reformulate its Neupro® (Rotigotine Transdermal System) before making it available in the U.S. market for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS). Release

> Exponential Pharma Ventures and Benu Biopharma have announced the formation of a new company, LipimetiX, to develop a series of peptides therapeutics that mimic the function of Apolipoprotein E (Apo E), focused on lipid-lowering treatments for high-risk cardiovascular patients. Release

> The US Military Malaria Vaccine Program has presented results of its study using the Bioject Medical Technologies’ Biojector®2000 needle-free injection therapy system with a recombinant DNA vaccine at two recent conferences. Release

> Using its proprietary Locked Nucleic Acid (LNA) drug platform and drug discovery engine, Santaris Pharma A/S has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), a new target for the treatment of high cholesterol. Santaris release

> Corealis Pharma, Inc. has consolidated its oral solid dosage formulation operations by acquiring a new 33,000 square-foot state-of-the-art pharmaceutical research facility in the Cité de la Biotech in Laval (Qc), Canada. Corealis release 

> Stemgent and Pfizer have announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Pfizer release